Price:
Rs. 11,550.00
Sample Type: EDTA BLOOD
Fasting Not Required
Notes: F0103
Frequently Asked Questions (FAQ's):
What does the FIP1L1-PDGFRA Gene Rearrangement test detect?
It detects the presence of FIP1L1-PDGFRA gene fusion in blood, performed with Metropolis Healthcare’s advanced molecular methods.
Why is this test important?
It helps diagnose specific blood cancers and guides targeted therapy with tyrosine kinase inhibitors.
What sample is required?
An EDTA blood sample is collected for DNA/RNA analysis.
Who should take this test?
Patients with unexplained eosinophilia, suspected myeloid malignancies, or those being evaluated for targeted therapy.
Is fasting required?
No fasting is required for this genetic test.
How long do results take at Metropolis Healthcare?
Results are typically available within 1–2 weeks depending on testing complexity.
How do the results help?
They support diagnosis, prognosis, and personalized treatment planning for hematologic disorders.
Can this test monitor treatment response?
Yes, Metropolis Healthcare can track the presence of the fusion gene to assess therapy effectiveness